Celgene Corp (NASDAQ:CELG)

93.99
Delayed Data
As of Aug 23
 -1.72 / -1.80%
Today’s Change
58.59
Today|||52-Week Range
98.97
+46.65%
Year-to-Date
Better Buy: Biogen vs. Celgene
2:00pm / MotleyFool.com - Paid Partner Content
5 Biggest New Drug Approvals Potentially on the Way in 2019
Aug 19 / MotleyFool.com - Paid Partner Content
The Zacks Analyst Blog Highlights: Celgene, Gilead, Vertex, Sarepta and Regeneron
Aug 22 / Zacks.com - Paid Partner Content
How Big Is Celgene's Latest Good News?
Aug 18 / MotleyFool.com - Paid Partner Content
BeiGene's NDA for Zanubrutinib Gets Priority Review From FDA
Aug 22 / Zacks.com - Paid Partner Content
Palatin's (PTN) to Report Q4 Earnings: What's in the Cards?
Aug 16 / Zacks.com - Paid Partner Content
Biotech Stock Roundup: CELG's Inrebic Gets FDA Nod, SRPT Suffers Setback & More
Aug 21 / Zacks.com - Paid Partner Content
Agios Rides High on Tibsovo Sales Amid Acute Competition
Aug 15 / Zacks.com - Paid Partner Content
Celgene Gets FDA Approval for Inrebic in Bone Marrow Cancer
Aug 19 / Zacks.com - Paid Partner Content
Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat
Aug 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close95.71
Today’s open95.65
Day’s range93.41 - 96.05
Volume4,651,491
Average volume (3 months)4,478,984
Market cap$66.7B
Data as of 4:00pm ET, 08/23/2019

Growth & Valuation

Earnings growth (last year)+49.83%
Earnings growth (this year)+22.10%
Earnings growth (next 5 years)+14.80%
Revenue growth (last year)+19.26%
P/E ratio12.9
Price/Sales3.08
Price/Book10.69

Competitors

 Today’s
change
Today’s
% change
ZTSZoetis Inc-3.57-2.82%
BMYBristol-Myers Squibb-1.28-2.67%
AGNAllergan-1.97-1.22%
TAKTakeda Pharmaceutica...-0.14-0.84%
Data as of 6:30pm ET, 08/23/2019

Financials

Next reporting dateOctober 28, 2019
EPS forecast (this quarter)$2.70
Annual revenue (last year)$15.3B
Annual profit (last year)$4.0B
Net profit margin26.46%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President, CEO &
COO
Mark J. Alles
CFO, Principal Accounting Officer &
Executive VP
David V. Elkins
Corporate headquarters
Summit, New Jersey

Forecasts